^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Glioma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to trametinib treatment in progressive pediatric low-grade glioma patients
Published date:
10/07/2020
Excerpt:
In this multi-center retrospective centrally reviewed study, we analyzed 18 patients treated with the MEKi trametinib for progressive pLGG...Alterations detected included 8 KIAA1549:BRAF-fusions, three NF1 alterations, one BRAF V600E mutation and one FGFR1 K654Q mutation....We observed 6 partial responses (PR), 2 minor responses (MR), and 10 stable diseases (SD) as best overall responses....Responses were observed in KIAA1549:BRAF- as well as neurofibromatosis type 1 (NF1)-driven tumors. Median treatment time was 12.5 months (range: 2 to 27 months)....
DOI:
10.1007/s11060-020-03640-3
